BPC December 31 update

Final pipeline updates for 2020 - AXSM LXRX RDHL

Price and Volume Movers

The final trading day of 2020, as expected, saw little to no significant news flow. A handful of pipeline updates are listed below.

Expect updates to return to normal next week with companies releasing 2021 pipeline timelines leading up to the J.P. Morgan Healthcare conference, being held virtually from January 11-15.

Thank you for your readership in 2020. We look forward to delivering our first newsletter for 2021 on January 4.

-

Hoth Therapeutics, Inc. (NASDAQ:HOTH) shares closed up 45% to $2.37 on news it has signed a production agreement for with Tergus Pharma for materials associated with its cancer candidate, HT-001. Development of HT-001 is still in the pre-clinical phase of development and intends to meet with the FDA during the first quarter of 2021 to discuss its planned Investigational New Drug (IND) application.

-

Major price movers (stocks priced > $1.00, volume > 50k listed on NASDAQ/NYSE):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Sigilon Therapeutics, Inc. (SGTX): $48.03; +29%.

Clearside Biomedical, Inc. (CLSD): $2.74; +18%.

Codiak BioSciences, Inc. (CDAK): $32.30; +15%.

EyePoint Pharmaceuticals, Inc. (EYPT): $6.58; +12%.

I-Mab (IMAB): $47.15; +11%.

DECLINERS:

Kymera Therapeutics, Inc. (KYMR): $62.00; -14%.

Anchiano Therapeutics Ltd. (ANCN): $1.73; -11%.

Replimune Group, Inc. (REPL): $38.15; -10%.

Annexon, Inc. (ANNX): $25.03; -9%.

Tiziana Life Sciences PLC (TLSA): $2.02; -9%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

AXSM – Axsome Therapeutics Inc.
AXS-05 ACCORD
Agitation in patients with Alzheimer’s disease (AD)

Phase 3 Phase 3 trial initiation announced December 31, 2020 with top-line data due 2H 2022.
$2.8 billion

AXSM – Axsome Therapeutics Inc.
AXS-07
Migraine

NDA Filing Phase 3 data released December 31, 2020. Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, at 2 hours. NDA filing due 1Q 2021.
$2.8 billion

LXRX – Lexicon Pharmaceuticals Inc.
LX9211
Post-herpetic neuralgia

Phase 2 Phase 2 trial initiation announced December 31, 2020 with data due 4Q 2021.
$1.2 billion

RDHL – Redhill Biopharma Ltd.
Opaganib
COVID-19

Phase 2a Phase 2 initial data released December 31, 2020.
$322.7 million

RDHL – Redhill Biopharma Ltd.
Opaganib
COVID-19

Phase 2/3 Phase 2/3 global trial top-line data 1Q 2021.
$322.7 million